INT26311

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1989
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 8
Total Number 22
Disease Relevance 16.35
Pain Relevance 1.94

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (ACE2) extracellular space (ACE2) extracellular region (ACE2)
plasma membrane (ACE2)
Anatomy Link Frequency
cartilage 1
heart 1
ACE2 (Homo sapiens)
Pain Link Frequency Relevance Heat
metalloproteinase 124 100.00 Very High Very High Very High
ischemia 270 99.88 Very High Very High Very High
Osteoarthritis 190 97.96 Very High Very High Very High
abdominal pain 1 96.24 Very High Very High Very High
anesthesia 15 88.80 High High
antagonist 47 78.08 Quite High
cINOD 1 75.00 Quite High
Arthritis 11 68.20 Quite High
rheumatoid arthritis 10 47.44 Quite Low
Bioavailability 4 33.64 Quite Low
Disease Link Frequency Relevance Heat
Cv Unclassified Under Development 270 99.88 Very High Very High Very High
Myocardial Infarction 50 99.58 Very High Very High Very High
Hypertension 131 99.24 Very High Very High Very High
INFLAMMATION 29 99.10 Very High Very High Very High
Cancer 24 98.68 Very High Very High Very High
Pulmonary Hypertension 465 98.60 Very High Very High Very High
Severe Acute Respiratory Syndrome 179 98.28 Very High Very High Very High
Osteoarthritis 194 97.96 Very High Very High Very High
Systemic Sclerosis 420 97.20 Very High Very High Very High
Vomiting 4 97.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Furthermore, the sera of the two patients lacked ACE2 activity.
Negative_regulation (lacked) of ACE2
1) Confidence 0.59 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911869 Disease Relevance 2.60 Pain Relevance 0.15
As shown in Figure 3d, the ACE2 levels in Patients 1 and 5, who were deficient in ACE2 activity (Figure 3c), were comparable with those in three healthy subjects, clearly indicating that the decreased ACE2 activity in the vasculopathy patients was due to a functional deficiency.
Negative_regulation (decreased) of ACE2
2) Confidence 0.43 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911869 Disease Relevance 0.14 Pain Relevance 0
Furthermore, the elevated ELISA scores for anti-ACE2 antibodies correlated with reduced ACE2 activity.
Negative_regulation (reduced) of ACE2
3) Confidence 0.43 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911869 Disease Relevance 1.26 Pain Relevance 0.08
First, the RFU value of the ACE2 enzyme activity, which was blocked by DX600 (Additional file 1), was determined in 18 patients with vasculopathy, in 16 control patients without vasculopathy, and in 26 healthy subjects.
Negative_regulation (blocked) of ACE2
4) Confidence 0.43 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911869 Disease Relevance 0.21 Pain Relevance 0.04
The IgG fraction from vasculopathy patients, but not from healthy subjects, inhibited ACE2 activities in vitro.
Negative_regulation (inhibited) of ACE2
5) Confidence 0.43 Published 2010 Journal Arthritis Res Ther Section Abstract Doc Link PMC2911869 Disease Relevance 0.83 Pain Relevance 0.07
As shown in Figure 3d, the ACE2 levels in Patients 1 and 5, who were deficient in ACE2 activity (Figure 3c), were comparable with those in three healthy subjects, clearly indicating that the decreased ACE2 activity in the vasculopathy patients was due to a functional deficiency.
Negative_regulation (deficient) of ACE2
6) Confidence 0.43 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911869 Disease Relevance 0.12 Pain Relevance 0
The inhibition of ACE2 by autoantibodies may result in reduced physiological levels of the vasoprotective agent Ang(1-7) in the local vascular milieu, which may induce vasculopathies in patients with underlying disease such as CTD.
Negative_regulation (inhibition) of ACE2 associated with disease
7) Confidence 0.43 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911869 Disease Relevance 1.58 Pain Relevance 0.13
The serum autoantibodies to ACE2 may therefore inhibit ACE2 activity, and the inhibition may be reversible after immunosuppressive therapy, based on the data from Patient 1.
Spec (may) Negative_regulation (inhibit) of ACE2
8) Confidence 0.43 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911869 Disease Relevance 1.35 Pain Relevance 0.08
As shown in Figure 3d, the ACE2 levels in Patients 1 and 5, who were deficient in ACE2 activity (Figure 3c), were comparable with those in three healthy subjects, clearly indicating that the decreased ACE2 activity in the vasculopathy patients was due to a functional deficiency.
Negative_regulation (deficient) of ACE2
9) Confidence 0.43 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911869 Disease Relevance 0.12 Pain Relevance 0
The anti-ACE2 antibodies were probably decreased as a result of immunosuppressive therapy using high-dose pulse steroids.
Negative_regulation (decreased) of ACE2
10) Confidence 0.43 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911869 Disease Relevance 0.28 Pain Relevance 0.08
Inhibition of ACE2 activity by IgG purified from patient serum
Negative_regulation (Inhibition) of ACE2
11) Confidence 0.43 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911869 Disease Relevance 1.09 Pain Relevance 0.05
Serum tests 2 months after the start of therapeutic intervention showed that the ELISA score for anti-ACE2 antibodies was reduced markedly (P < 0.05) (Figure 4a) and the ACE2 activity had recovered significantly (P < 0.05) (Figure 4b), compared with the values before therapy.
Negative_regulation (recovered) of ACE2
12) Confidence 0.43 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911869 Disease Relevance 0.33 Pain Relevance 0.09
The patient was not receiving angiotensin-converting enzyme inhibitors.
Negative_regulation (inhibitors) of angiotensin-converting enzyme
13) Confidence 0.42 Published 2005 Journal Allergol Immunopathol (Madr) Section Abstract Doc Link 15777525 Disease Relevance 1.06 Pain Relevance 0.10
Secondary outcomes could be classified into five groups: (1) subgroup analysis of primary outcome where all patients with diabetes were excluded (patients with untreated diabetes were excluded from the main analysis); (2) the proportion of patients who, within 4 mo, reached recommended blood-pressure goals; (3) the proportion of patients who, within 4 mo, were not started on a second antihypertensive drug; (4) the proportion of patients with heart failure being prescribed an angiotensin-converting enzyme (ACE) inhibitor (ATC groups C09A and C09B) within 3 mo of receiving the diagnosis; and (5) the proportion of patients with coronary heart disease being prescribed a beta-blocking agent (ATC group C07) within 3 mo of receiving the diagnosis (proxy measures for inappropriate prescribing).
Negative_regulation (inhibitor) of angiotensin-converting enzyme in heart associated with coronary artery disease, diabetes mellitus and myocardial infarction
14) Confidence 0.41 Published 2007 Journal PLoS Medicine Section Body Doc Link PMC1904466 Disease Relevance 0.38 Pain Relevance 0
We could not determine whether their hypertension was essential hypertension, or was caused by steroid therapy or ACE2 inhibition.
Negative_regulation (inhibition) of ACE2 associated with hypertension
15) Confidence 0.38 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911869 Disease Relevance 1.52 Pain Relevance 0.13
The IgG fractions from the vasculopathy patients, but not from the healthy subjects, suppressed the rACE2 enzyme activity significantly compared with that in the absence of IgG (Figure 2b).


Negative_regulation (suppressed) of rACE2
16) Confidence 0.37 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911869 Disease Relevance 0.44 Pain Relevance 0.04
The activity of standard rACE2 was measured in 5 ?
Negative_regulation (measured) of rACE2
17) Confidence 0.37 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911869 Disease Relevance 0.58 Pain Relevance 0.05
Also, antibodies against ACE2, but not inhibitors binding to the active site of ACE2 may be useful for the development of therapeutic strategies.


Neg (not) Negative_regulation (inhibitors) of ACE2
18) Confidence 0.20 Published 2005 Journal Respir Res Section Body Doc Link PMC548145 Disease Relevance 0.76 Pain Relevance 0
Tiaprofenic acid, a nonsteroidal antiinflammatory drug belonging to the propionic acid class, reduced both the proteoglycan catabolism (26 micrograms/ml, 6.3 +/- 1.4%; 2.6 micrograms/ml, 7.1 +/- 1.4%) and metalloprotease activity (26 micrograms/ml, 1.1 +/- 0.3 units/mg wet weight; 2.6 micrograms/ml, 1.1 +/- 0.2 units/mg wet weight) induced by IL-1 (10.2 +/- 2.3%; 1.7 +/- 0.4 units/mg wet weight).
Negative_regulation (reduced) of metalloprotease associated with inflammation
19) Confidence 0.14 Published 1989 Journal J Rheumatol Suppl Section Abstract Doc Link 2553967 Disease Relevance 0.45 Pain Relevance 0.07
The tissue inhibitors of metalloprotease 1, 2 and 3 (TIMP-1, -2, -3) and tumor suppressor protein genes have been cloned and characterized from shark cartilage extracts [52, 60, 61].
Negative_regulation (inhibitors) of metalloprotease in cartilage associated with cancer
20) Confidence 0.01 Published 2009 Journal Marine Drugs Section Body Doc Link PMC2707034 Disease Relevance 0.10 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox